The European Medicines Agency (EMA) announced on Tuesday 4 May that it had initiated a rolling review of the Covid-19 vaccine that has been developed by the Chinese pharmaceutical company Sinovac.
The decision, it explained in a statement, was prompted by preliminary results from laboratory and clinical studies that suggests the vaccine in question “triggers the production of antibodies” against SARS-CoV-2 and “may help protect against the disease”.
In order to assess the...